Catenae Innovation PLC
("Catenae", or the "Company")
Update re Issue of Warrants
Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of digital media and technology, announces that, further to the announcement made on 16 October 2020, the Company has issued a warrant over 2,000,000 new ordinary shares in the Company (the "Warrant").
The Warrant is exercisable at a price of 2.5 pence per ordinary share and will vest with immediate effect. The Warrant may be exercised at any date to 8 April 2023.
The warrant over 10,000,000 new ordinary shares to be issued to a related party of BHA-Medical (Pty) Limited referred to in the 16 October 2020 announcement remains unissued. A further announcement will be made in due course.
- Ends -
This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The person who arranged for release of this announcement on behalf of the Company was Guy Meyer, Chief Executive Officer of the Company and the Directors of the Company are responsible for the release of this announcement.
For further information please contact:
| Catenae Innovation PLC | +44 (0)191 580 8545 |
| Guy Meyer, Chief Executive Officer | |
| Cairn Financial Advisers LLP (Nominated Adviser) | +44(0)20 7213 0880 |
| Liam Murray / Jo Turner | |
| | |
| Brandon Hill Capital Limited, Broker | +44 (0)20 3463 5000 |
| Andy Gutmann | |
| | |
| Yellow Jersey PR (PR & IR) | +44 (0)20 3004 9512 |
| Sarah Hollins / Annabel Atkins / Matthew McHale | |
Notes to Editors:
About Catenae Innovation PLC
Catenae Innovation is an AIM quoted provider of digital media and technology services. Catenae use the power of blockchain to deliver solutions where its people-centric technology enables trust and certainty allowing organisations to gain better control over their operations, manage staff and safely welcome customers.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.